Comparison of multiple-dose and once-daily nitrate therapy in patients with stable angina pectoris: effects on quality-of-life indices

Niemeyer, Menco G.; Kleinjans, H. A. J.; Ree, Rob de; Zwinderman, Aeilko H.; Cleophas, Ton J.; Wall, Ernst E. van der

doi:10.1016/s0011-393x(96)80111-1

Cited by 7 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In brief, published results 12,13 show that the slow-release formulation of ISMN produced a 17% greater improvement in mobility, a 36% decrease of anginal pain index, a 35% greater reduction of anginal pain between the hours of 8 and 10 AM, a 13% greater improvement in psychological well-being, and a 50% greater improvement of patient compliance (p values were between p = 0.03 and < 0.001). 12,13 For the purpose of the multiple regression analysis, the summary odds ratios of QOL scores were added up and linearly transformed on a scale of 0 to 10 and subsequently used as a dependent variables (namely response variables). Independent variables (namely explanatory variables) are listed in Table II.…”

Section: Methodsmentioning

confidence: 99%

Factors Influencing Efficacy of Nitrate Therapy for Stable Angina Pectoris: A Multiple Linear Regression Analysis

Jansen¹,

Niemeyer

Cleophas

et al. 2000

Angiology

Self Cite

View full text Add to dashboard Cite

In an open-label self-controlled study of 1,350 patients with stable angina pectoris (SAP), we previously demonstrated that 50 mg of isosorbide mononitrate (ISMN) slow release formulation once daily not only provided a better antianginal effect but also a better quality of life (QOL) than did the daily administration of multiple small doses of the compound. It is unknown whether certain patient characteristics contribute to this benefit. The objective of this article was to determine what independent factors contribute to this benefit. Multiple linear regression analysis was performed on the data from these 1,350 patients. Quality of life was assessed by the Marquis QOL-questionnaire for patients with angina and included the domains of immobility, pain, and psychological distress. For the purpose of this study, overall QOL was calculated as the pooled sums of the domain scores and expressed as mean scores on an ordinal scale of 10. Age did not influence the beneficial effect of nitrate therapy on QOL. Neither did gender, rhythmic disturbances, peripheral artery disease, or the concomitant use of calcium channel blockers or beta blockers. New York Heart Association (NYHA) angina classification was an independent variable: patients with a NYHA class I or II benefited less than did patients with NYHA III or IV (p = 0.02). Obese patients as well as hypertensive patients benefited less (p = 0.04 and 0.02), and smokers tended to benefit less also (p = 0.08). In contrast, hypercholesterolemia and diabetes mellitus improved the beneficial effect of nitrates on QOL (p = 0.03 and 0.05). The authors conclude that patients with coronary artery disease (CAD) and concomitant diabetes mellitus or hypercholesterolemia, a category particularly prone to early endothelial dysfunction and thus dysfunctional endogenous nitric oxide (NO) production, may benefit more from NO-donor therapy than patients without such concomitant conditions.

show abstract

Section: Methodsmentioning

confidence: 99%

Factors Influencing Efficacy of Nitrate Therapy for Stable Angina Pectoris: A Multiple Linear Regression Analysis

Jansen¹,

Niemeyer

Cleophas

et al. 2000

Angiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Better patient compliance might be expected with once‐daily nitrate therapy than with multiple doses, but how does this measure up in terms of symptom control and quality of life indices? Niemeyer et al , 27 at 55 hospitals in the Netherlands, carried out a multicentre comparison of two treatment options. The 1212 patients all had documented coronary artery disease and stable angina, which was being treated with beta‐blockers, calcium channel blockers and/or short‐acting nitrates.…”

Section: Quality Of Life With Isosorbide Mononitratementioning

confidence: 99%

“…Patients' view of quality‐of‐life parameters after administration of ISMN over a three‐month period following three months of multiple dose nitrates 27 …”

Section: Isosorbide Mononitrate In Heart Failurementioning

confidence: 99%

A Sustained Release Formulation of Isosorbide‐5‐mononitrate With a Rapid Onset of Action

Arthur

Mehmel

1999

Int J Clinical Practice

View full text Add to dashboard Cite

SUMMARYThe clinical efficacy of a combined immediate‐release and sustained‐release preparation of isosorbide‐5‐mononitrate for angina pectoris is observed within a few minutes of administration. The preparation reduces the number of silent and painful ischaemic episodes and increases work and exercise capacity. The pharmacokinetic profiles accord with the circadian variation in cardiovascular disease. Drug levels fall significantly at night and tolerance to the haemodynamic and antianginal effects is not seen. Once‐daily administration is appreciated by patients. The preparation also shows promise in treating heart failure.

show abstract

Linear Scale Assessment of Relevant Domains of Quality of Life an example

Cleophas

1999

Human Experimentation

View full text Add to dashboard Cite

Comparison of multiple-dose and once-daily nitrate therapy in patients with stable angina pectoris: effects on quality-of-life indices

Cited by 7 publications

References 21 publications

Factors Influencing Efficacy of Nitrate Therapy for Stable Angina Pectoris: A Multiple Linear Regression Analysis

Factors Influencing Efficacy of Nitrate Therapy for Stable Angina Pectoris: A Multiple Linear Regression Analysis

A Sustained Release Formulation of Isosorbide‐5‐mononitrate With a Rapid Onset of Action

Linear Scale Assessment of Relevant Domains of Quality of Life an example

Contact Info

Product

Resources

About